Transient sialoadenitis: A complication of 131I- metaiodobenzylguanidine therapy

Pediatric Blood and Cancer

Volumn 50, Issue 6, 2008, Pages 1271-1273

  Modak, Shakeel ^a   Pandit Taskar, Neeta ^a   Kushner, Brian H ^a   Kramer, Kim ^a   Smith Jones, Peter ^a   Larson, Steven ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Malignant pheochromocytoma; MIBG therapy; Neuroblastoma; Sialoadenitis

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; AMYLASE; LIOTHYRONINE; TRIACYLGLYCEROL LIPASE;

ADOLESCENT; AMYLASE BLOOD LEVEL; ARTICLE; CANCER RADIOTHERAPY; CHEWING DISCOMFORT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPHAGIA; ERYTHEMA; FACIAL DISCOMFORT; FEMALE; HUMAN; HYPERAMYLASEMIA; JAW PAIN; MALE; NAUSEA AND VOMITING; NEUROBLASTOMA; PAROTID ENLARGEMENT; PAROTID SWELLING; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SALIVATION; SIALOADENITIS; SIDE EFFECT; SINGLE DRUG DOSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; XEROSTOMIA;

3-IODOBENZYLGUANIDINE; ADOLESCENT; AMYLASES; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; NEUROBLASTOMA; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; SIALADENITIS;

EID: 42349094437     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21391     Document Type: Article

References (19)

1. Matthay KK, Yanik G, Messina J, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131- metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 2007;25:1054-1060.
2. Howard JP, Maris JM, Kersun LS, et al. Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 2005;44:232-239.
3. Fitzgerald PA, Goldsby RE, Huberty JP, et al. Malignant pheochromocytomas and paragangliomas: A phase II study of therapy with high-dose 131I-metaiodobenzylguanidine [131I-MIBG]. Ann NY Acad Sci 2006;1073:465-490.
4. Garaventa A, Gambini C, Villavecchia G, et al. Second malignancies in children with neuroblastoma after combined treatment with 131I- metaiodobenzylguanidine. Cancer 2003;97:1332-1338.
5. DuBois SG, Messina J, Maris JM, et al. Hematologic toxicity of high-dose iodine-13I-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004;22:2452-2460.
6. Garaventa A, Bellagamba O, Lob Piccolo MS, et al. 131 I-metaiodobenzylguanidine [131I-MIBG] therapy for residual neuroblastoma: A mono institutional experience with 43 patients. Br J Cancer 1999;81:1378-1384.
7. Matthay K, DeSantes K, Hasegawa B, et al. Phase I dose escalation of 131 I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuoblastoma. J Clin Oncol 1998;16:229-236.
8. Alexander C, Bader JB, Schaefer A, et al. long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998;39:1551-1554.
9. Hyer S, Kong A, Pratt B, et al. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol [R Coll Radiol] 2007;19:83-86.
10. Nakajo M, Shapiro B, Sisson JC, et al. Salivary gland accumulation of meta-[131I]iodobenzylguanidine. J Nucl Med 1984;25:2-6.
11. Sisson JC, Wieland DM, Jaques S, Jr., et al. Radiolabeled metaiodobenzylguanidine and the adrenergic neurons of salivary glands. Am J Physiol Imaging 1987;2:1-9.
12. Elgazzar AH, Gelfand MJ, Washburn LC, et al. I-123 MIBG scintigraphy in adults. A report of clinical experience. Clin Nucl Med 1995;20:147-152.
13. Junglee D, Katrak A, Mohiuddin J, et al. Salivary amylase and pancreatic enzymes in serum after total body irradiation. Clin Chem 1986;32:609-610.
14. Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003;13:265-271.
15. De La Vieja A, Dohan O, Levy O, et al. Molecular analysis of the sodium/iodide symporter: Impact on thyroid and extrathyroid pathophysiology. Physiol Rev 2000;80:1083-1105.
16. Carter JE. Iodide "mumps". N Engl J Med 1961;264:987-988.
17. Goldberg RE, Miraldi F. Radionuclide imaging of potassium iodide-induced sialadenitis. Clin Nucl Med 1987;12:370-372.
18. Lin WY, Shen YY, Wang SJ. Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 1996;21:780-782.
19. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986;59:45-51.